Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
ACTIVE_NOT_RECRUITING
Status
Conditions
- Diffuse Large B Cell Lymphoma
Interventions
- DRUG: Tafasitamab
- DRUG: Lenalidomide
Sponsor
Incyte Corporation